Eric Adler - Feb 2, 2024 Form 4 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Signature
/s/ Jenny Robertson, attorney-in-fact
Stock symbol
LXEO
Transactions as of
Feb 2, 2024
Transactions value $
$0
Form type
4
Date filed
2/6/2024, 05:56 PM
Previous filing
Nov 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXEO Common Stock Award $0 +26.9K $0.00 26.9K Feb 2, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LXEO Employee Stock Option (right to buy) Award $0 +161K $0.00 161K Feb 2, 2024 Common Stock 161K $17.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2025, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date.
F2 25% of the shares underlying the option vest and become exercisable on February 2, 2025, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.